SAN ANTONIO — A recently approved breast cancer drug called lapatinib may serve as a valuable partner for letrozole, a standard frontline drug for the disease, according to a study of patients whose cancer has spread.
Patients with metastatic breast cancer are destined to return to chemotherapy, and this drug combination seems to significantly delay that day for patients who have a certain form of the disease, says medical oncologist Stephen Johnston of the Royal Marsden NHS Foundation Trust in London.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.